Levosimendan and Myocardial Protection

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Myocardial Protection
Interventions
DRUG

levosimendan

24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB

DRUG

Placebo

an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB

Trial Locations (1)

00155

"University of Rome Sapienza", Rome

All Listed Sponsors
collaborator

University College London Hospitals

OTHER

lead

University of Roma La Sapienza

OTHER

NCT00610350 - Levosimendan and Myocardial Protection | Biotech Hunter | Biotech Hunter